MedPath

Romiplostim

Generic Name
Romiplostim
Brand Names
Nplate
Drug Type
Biotech
CAS Number
267639-76-9
Unique Ingredient Identifier
GN5XU2DXKV
Background

Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues. Each subunit consists of an IgG1 Fc carrier domain that is covalently attached to a polypeptide sequence that contains two binding domains to interact with thrombopoietin receptor c-Mpl. Each domain consists of 14 amino acids. Interestingly, romiplostim's amino acid sequence is not similar to that of endogenous thrombopoietin. Romiplostim is produced by recombinant DNA technology in Escherichia coli. FDA approved on August 22, 2008.

Indication

Treatment of chronic immune thrombocytopenic purpura.

Associated Conditions
Chronic immune thrombocytopenia, Refractory immune thrombocytopenia

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Phase 2
Not yet recruiting
Conditions
Cancer Treatment-induced Thrombocytopenia (CTIT)
Interventions
First Posted Date
2025-03-27
Last Posted Date
2025-03-28
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
97
Registration Number
NCT06898983
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China

FRIENDS-01:A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Phase 3
Not yet recruiting
Conditions
CTIT: Cancer Therapy Induced Thrombocytopenia
Interventions
First Posted Date
2025-01-06
Last Posted Date
2025-01-06
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
88
Registration Number
NCT06759636
Locations
🇨🇳

The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT

Phase 2
Recruiting
Conditions
Platelet Recovery After Umbilical Cord Blood Transplantation
Interventions
First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Anhui Provincial Hospital
Target Recruit Count
34
Registration Number
NCT06693791
Locations
🇨🇳

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

Phase 4
Not yet recruiting
Conditions
Aplastic Anemia
Interventions
First Posted Date
2024-08-02
Last Posted Date
2024-08-02
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
40
Registration Number
NCT06535685
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study

Phase 4
Not yet recruiting
Conditions
Aplastic Anemia
Interventions
First Posted Date
2024-07-24
Last Posted Date
2024-07-24
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
40
Registration Number
NCT06516484
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

Phase 3
Active, not recruiting
Conditions
Safety Issues
Immunogenicity
Drug Effect
Interventions
Drug: GP404141
First Posted Date
2024-07-11
Last Posted Date
2024-07-11
Lead Sponsor
Geropharm
Target Recruit Count
160
Registration Number
NCT06497036
Locations
🇷🇺

Kaluga Regional Clinical Hospital, Kaluga, Russian Federation

🇷🇺

Samara State Medical University" of the Ministry of Health of the Russian Federation, Samara, Russian Federation

🇷🇺

City Clinical Hospital S.P. Botkin of the Moscow City Health Department, Moscow, Russian Federation

and more 3 locations

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

Phase 2
Not yet recruiting
Conditions
Cancer Treatment-Induced Thrombocytopenia
Interventions
Drug: QL0911 plus Placebo
Drug: Placebo
First Posted Date
2024-06-13
Last Posted Date
2024-06-13
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
235
Registration Number
NCT06456528

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Phase 3
Not yet recruiting
Conditions
CTIT-Chemotherapy Induced Thrombocytopenia
Interventions
First Posted Date
2024-06-04
Last Posted Date
2024-06-04
Lead Sponsor
Shandong University
Target Recruit Count
60
Registration Number
NCT06440824

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Phase 2
Recruiting
Conditions
Splenomegaly
Myelofibrosis
Interventions
First Posted Date
2024-04-03
Last Posted Date
2025-05-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06345495
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Romiplostim in Chemotherapy-Induced Thrombocytopenia

Phase 3
Recruiting
Conditions
Chemotherapy-induced Thrombocytopenia
Solid Malignancy
Interventions
First Posted Date
2024-01-11
Last Posted Date
2024-01-11
Lead Sponsor
Ain Shams University
Target Recruit Count
30
Registration Number
NCT06201663
Locations
🇪🇬

Ain Shams University Children's Hospital, Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath